Assessing the efficacy of different medications in decreasing complications of transureteral lithotripsy

Comparison the effect of single dose medication in decreasing urgent ureteroscopy complications, a double blind randomized clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20161221031505N1

Enrollment

400

Registered

2022-06-25

Start date

2022-07-23

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ureteral stone. N 21

Interventions

Intervention 1: Intervention group number 1: 1 amp. Hyoscine 20 mg made by Exir company diluted in one liter normal saline is infused via vein catheter 1 hour before intervention. Intervention 2: Inte

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Candidates of transureteral lithotripsy

Exclusion criteria

Exclusion criteria: Renal dysfunction, Creatinine more than 1.5 mg/dl Previous ureteral intervention Having Double J or ureteral catheter age higher than 65 Weight less than 50 kg Contraindication or allergy to medications used in project History of using medications before intervention Patient does not want to participate in study

Design outcomes

Primary

Measure	Time frame
Reducing damage to the bladder. Timepoint: During TUL. Method of measurement: Observing procedure.;Reducing damage to the ureteral entrance to the bladder. Timepoint: During TUL. Method of measurement: Observing procedure.;Reducing ureteral mucosa injury. Timepoint: During transurethral lithotripsy. Method of measurement: Observing the procedure.;Reducing ureteral perforation. Timepoint: During transurethral lithotripsy. Method of measurement: Observing the procedure.;Reducing ureteral stone riching failure. Timepoint: During transurethral lithotripsy. Method of measurement: Observation the procedure.;Reducing inability to enter the ureter. Timepoint: During transurethral lithotripsy. Method of measurement: Observation during procedure.;Reducing ureteral avulsion. Timepoint: During transurethral lithotripsy. Method of measurement: Observing during procedure.;Reducing the need for a narrower ureteroscope. Timepoint: During transurethral lithotripsy. Method of measurement: Observing during procedure.	—

Measure

Time frame

Reducing damage to the bladder. Timepoint: During TUL. Method of measurement: Observing procedure.;Reducing damage to the ureteral entrance to the bladder. Timepoint: During TUL. Method of measurement: Observing procedure.;Reducing ureteral mucosa injury. Timepoint: During transurethral lithotripsy. Method of measurement: Observing the procedure.;Reducing ureteral perforation. Timepoint: During transurethral lithotripsy. Method of measurement: Observing the procedure.;Reducing ureteral stone riching failure. Timepoint: During transurethral lithotripsy. Method of measurement: Observation the procedure.;Reducing inability to enter the ureter. Timepoint: During transurethral lithotripsy. Method of measurement: Observation during procedure.;Reducing ureteral avulsion. Timepoint: During transurethral lithotripsy. Method of measurement: Observing during procedure.;Reducing the need for a narrower ureteroscope. Timepoint: During transurethral lithotripsy. Method of measurement: Observing during procedure.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamed Akhavizadegan

Tehran University of Medical Sciences

h-akhavizadegan@tums.ac.ir+98 21 6312 1538

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026